Oncology Division
Alphabetical list (active faculty):   
Ramaswamy Govindan

Ramaswamy Govindan, MD

Anheuser Busch Endowed Chair in Medical Oncology


Department of Medicine

Oncology Division

Medical Oncology

Research Interests

  • Lung cancer
  • Cancer genomics
  • Lung cancer
  • Cancer genomics


  • 314-747-7405 (office)
  • 314-362-3895 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)


As a medical oncologist interested in thoracic malignancies, I have led a number of institutional and multi- center phase II and III studies in lung cancer over the past decade. Working with The McDonnell Genome Institute at the Washington University School of Medicine and with The Cancer Genome Atlas (TCGA) project (as a co-chair) sponsored by the NCI, I am actively involved in sequencing the whole genomes and exomes of several hundred patients with lung cancer. In addition, I am leading the efforts to move personalized therapies in early stage and locally advanced lung cancer. I am the Principal Investigator for the NCI funded large phase III randomized ALCHEMIST trial to study the role of erlotinib in patients with early stage EGFR mutated lung cancer. We have recently reported for the first-time mechanistic basis for acquired resistance to chemotherapy in patients with relapsed small cell lung cancer using whole exome and transcriptome sequencing. I am the Principal Investigator for the NCI funded consortium for the development of patient-derived xenograft (PDX) models to translate rapidly discoveries from bench to bedside. I have led Team Science effort through U01/U54 funded projects and the TCGA.